Download PDF
CC BY-NC-ND 4.0 · J Neuroanaesth Crit Care 2019; 06(02): 160-166
DOI: 10.1055/s-0039-1688896
Review Article
Indian Society of Neuroanaesthesiology and Critical Care

Management of Guillain-Barré Syndrome

Kadarapura N. Gopalakrishna
1   Department of Neuroanaesthesia and Neurocritical Care, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, India
,
Venkatapura J. Ramesh
1   Department of Neuroanaesthesia and Neurocritical Care, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, India
› Author Affiliations
Further Information

Publication History

Received: 11 February 2019

Accepted after revision: 15 March 2019

Publication Date:
03 June 2019 (online)

   Permissions and Reprints

Abstract

Guillain-Barré syndrome (GBS) is the most common, immune-mediated acute polyneuropathy characterized by variable degree of motor weakness, often presenting with quadriparesis. GBS with respiratory failure requiring endotracheal intubation with mechanical ventilation is common, affecting approximately 30% of patients. In addition, they present with sensory features, cranial nerve involvement, and autonomic disturbance. The majority of GBS patients have preceding respiratory tract infection or gastroenteritis. The diagnosis of GBS is based on clinical features supported by cerebrospinal fluid (CSF) examination and nerve conduction studies. Early course of the GBS requires meticulous monitoring and early initiation of immunotherapy. Plasma exchange (PE) and intravenous immunoglobulin (IVIg) are the proven therapies, and both have been shown to be equally effective. General supportive care is an important part of management of GBS. A multidisciplinary approach to prevent and manage potential complications in rapidly progressing GBS is important to reduce morbidity and mortality.

Keywords

Guillain-Barré syndrome - immunotherapy - plasma exchange - immunoglobulin
 

  • References

  • 1 Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet 2005; 366 (9497) 1653-1666
    CrossrefPubMedGoogle Scholar
  • 2 Sejvar J, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011; 36 (02) 123-133
    CrossrefPubMedGoogle Scholar
  • 3 Hallas J, Bredkjaer C, Friis ML. Guillain-Barré syndrome: diagnostic criteria, epidemiology, clinical course and prognosis. Acta Neurol Scand 1988; 78 (02) 118-122
    CrossrefPubMedGoogle Scholar
  • 4 Govoni V, Granieri E. Epidemiology of the Guillain-Barré syndrome. Curr Opin Neurol 2001; 14 (05) 605-613
    CrossrefPubMedGoogle Scholar
  • 5 Esposito S, Longo MR. Guillain-Barré syndrome. Autoimmun Rev 2017; 16 (01) 96-101
    CrossrefPubMedGoogle Scholar
  • 6 Jacobs BC, Rothbarth PH, van der Meché FG. et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 1998; 51 (04) 1110-1115
    CrossrefPubMedGoogle Scholar
  • 7 Katirji B, Koontz D. Disorders of peripheral nerves. In: Robert BD, Gerald MF, Joseph J, John CM. eds. Bradley's Neurology in Clinical Practice. 6th ed.. Philadelphia, PA: Elsevier Saunders; 2012: 1955-1964
    Google Scholar
  • 8 Willison HJ, Goodyear CS. Glycolipid antigens and autoantibodies in autoimmune neuropathies. Trends Immunol 2013; 34 (09) 453-459
    CrossrefPubMedGoogle Scholar
  • 9 Blum S, McCombe PA. Genetics of Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): current knowledge and future directions. J Peripher Nerv Syst 2014; 19 (02) 88-103
    CrossrefPubMedGoogle Scholar
  • 10 Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol 2001; 58 (06) 893-898
    CrossrefPubMedGoogle Scholar
  • 11 Kieseier BC, Wiendl H, Hartung HP. The inflamed peripheral nervous syste update on immune therapies. Curr Opin Neurol 2006; 19 (05) 433-436
    CrossrefPubMedGoogle Scholar
  • 12 Souayah N, Nasar A, Suri MF, Qureshi AI. Guillain-Barre syndrome after vaccination in United States a report from the CDC/FDA Vaccine Adverse Event Reporting System. Vaccine 2007; 25 (29) 5253-5255
    CrossrefPubMedGoogle Scholar
  • 13 van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008; 7 (10) 939-950
    CrossrefPubMedGoogle Scholar
  • 14 Ho TW, Mishu B, Li CY. et al. Guillain-Barré syndrome in northern China. relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995; 118 (Pt 3) 597-605
    CrossrefPubMedGoogle Scholar
  • 15 van den Berg B, van der Eijk A, Pas SD. et al. Guillain-Barré syndrome associated with preceding hepatitis E virus infection. Neurology 2014; 82 (06) 491-497
    CrossrefPubMedGoogle Scholar
  • 16 Muñoz LS, Parra B, Pardo CA. Neuroviruses Emerging in the Americas Study. Neurological implications of Zika virus infection in Adults. J Infect Dis 2017; 216 (Suppl. 10) S897-S905
    CrossrefPubMedGoogle Scholar
  • 17 Mori M, Kuwabara S, Miyake M. et al. Haemophilus influenzae infection and Guillain-Barré syndrome. Brain 2000; 123 (Pt 10) 2171-2178
    CrossrefPubMedGoogle Scholar
  • 18 Meyer Sauteur PM, Huizinga R, Tio-Gillen AP. et al. Mycoplasma pneumoniae triggering the Guillain-Barré syndrome: a case-control study. Ann Neurol 2016; 80 (04) 566-580
    CrossrefPubMedGoogle Scholar
  • 19 Goodfellow JA, Willison HJ. Guillain-Barré syndrome: a century of progress. Nat Rev Neurol 2016; 12 (12) 723-731
    CrossrefPubMedGoogle Scholar
  • 20 Doets AY, Jacobs BC, van Doorn PA. Advances in management of Guillain-Barré syndrome. Curr Opin Neurol 2018; 31 (05) 541-550
    CrossrefPubMedGoogle Scholar
  • 21 Baker MG, Kvalsvig A, Zhang J, Lake R, Sears A, Wilson N. Declining Guillain-Barré syndrome after campylobacteriosis control, New Zealand, 1988-2010. Emerg Infect Dis 2012; 18 (02) 226-233
    CrossrefPubMedGoogle Scholar
  • 22 Pithadia AB, Kakadia N. Guillain-Barré syndrome (GBS). Pharmacol Rep 2010; 62 (02) 220-232
    CrossrefPubMedGoogle Scholar
  • 23 Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27 (Suppl) S21-S24
    CrossrefPubMedGoogle Scholar
  • 24 van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 2014; 10 (08) 469-482
    CrossrefPubMedGoogle Scholar
  • 25 Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet 2016; 388 10045 717-727
    CrossrefPubMedGoogle Scholar
  • 26 Moulin DE, Hagen N, Feasby TE, Amireh R, Hahn A. Pain in Guillain-Barré syndrome. Neurology 1997; 48 (02) 328-331
    CrossrefPubMedGoogle Scholar
  • 27 Ruts L, Drenthen J, Jongen JL. et al; Dutch GBS Study Group. Pain in Guillain-Barré syndrome: a long-term follow-up study. Neurology 2010; 75 (16) 1439-1447
    CrossrefPubMedGoogle Scholar
  • 28 Hughes RA, Wijdicks EF, Benson E. et al; Multidisciplinary Consensus Group. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol 2005; 62 (08) 1194-1198
    CrossrefPubMedGoogle Scholar
  • 29 Roodbol J, de Wit MC, Aarsen FK, Catsman-Berrevoets CE, Jacobs BC. Long-term outcome of Guillain-Barré syndrome in children. J Peripher Nerv Syst 2014; 19 (02) 121-126
    CrossrefPubMedGoogle Scholar
  • 30 Eldar AH, Chapman J. Guillain Barré syndrome and other immune mediated neuropathies: diagnosis and classification. Autoimmun Rev 2014; 13 (04) (05) 525-530
    CrossrefPubMedGoogle Scholar
  • 31 Wong AH, Umapathi T, Nishimoto Y, Wang YZ, Chan YC, Yuki N. Cytoalbuminologic dissociation in Asian patients with Guillain-Barré and Miller Fisher syndromes. J Peripher Nerv Syst 2015; 20 (01) 47-51
    CrossrefPubMedGoogle Scholar
  • 32 Hadden RD, Cornblath DR, Hughes RA. et al; Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 1998; 44 (05) 780-788
    CrossrefPubMedGoogle Scholar
  • 33 Vucic S, Cairns KD, Black KR, Chong PS, Cros D. Neurophysiologic findings in early acute inflammatory demyelinating polyradiculoneuropathy. Clin Neurophysiol 2004; 115 (10) 2329-2335
    CrossrefPubMedGoogle Scholar
  • 34 Kokubun N, Nishibayashi M, Uncini A, Odaka M, Hirata K, Yuki N. Conduction block in acute motor axonal neuropathy. Brain 2010; 133 (10) 2897-2908
    CrossrefPubMedGoogle Scholar
  • 35 Kokubun N, Shahrizaila N, Hirata K, Yuki N. Reversible conduction failure is distinct from neurophysiological patterns of recovery in mild demyelinating Guillain-Barré syndrome. J Neurol Sci 2013; 326 (01) (02) 111-114
    CrossrefPubMedGoogle Scholar
  • 36 Jacobs BC, van Doorn PA, Schmitz PI. et al. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann Neurol 1996; 40 (02) 181-187
    CrossrefPubMedGoogle Scholar
  • 37 Galassi G, Genovese M, Ariatti A, Malagoli M. Early imaging in paraparetic Guillain-Barré syndrome. Acta Neurol Belg. 2017
    PubMedGoogle Scholar
  • 38 Berciano J, Gallardo E, Orizaola P. et al. Early axonal Guillain-Barré syndrome with normal peripheral conduction: imaging evidence for changes in proximal nerve segments. J Neurol Neurosurg Psychiatry 2016; 87 (05) 563-565
    CrossrefPubMedGoogle Scholar
  • 39 Saifudheen K, Jose J, Gafoor VA, Musthafa M. Guillain-Barre syndrome and SIADH. Neurology 2011; 76 (08) 701-704
    CrossrefPubMedGoogle Scholar
  • 40 Bosch EP. Guillain-Barre syndrome: an update of acute immune-mediated polyradiculoneuropathies. Neurologist 1998; 4 (11) 211-226
    CrossrefPubMedGoogle Scholar
  • 41 Walgaard C, Lingsma HF, Ruts L. et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol 2010; 67 (06) 781-787
    PubMedGoogle Scholar
  • 42 Green C, Baker T, Subramaniam A. Predictors of respiratory failure in patients with Guillain-Barré syndrome: a systematic review and meta-analysis. Med J Aust 2018; 208 (04) 181-188
    CrossrefPubMedGoogle Scholar
  • 43 Sharshar T, Chevret S, Bourdain F, Raphaël JC. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Early predictors of mechanical ventilation in Guillain-Barré syndrome. Crit Care Med 2003; 31 (01) 278-283
    CrossrefPubMedGoogle Scholar
  • 44 Kannan Kanikannan MA, Durga P, Venigalla NK, Kandadai RM, Jabeen SA, Borgohain R. Simple bedside predictors of mechanical ventilation in patients with Guillain-Barre syndrome. J Crit Care 2014; 29 (02) 219-223
    CrossrefPubMedGoogle Scholar
  • 45 Holdgaard HO, Pedersen J, Jensen RH. et al. Percutaneous dilatational tracheostomy versus conventional surgical tracheostomy. A clinical randomised study. Acta Anaesthesiol Scand 1998; 42 (05) 545-550
    CrossrefPubMedGoogle Scholar
  • 46 Liu J, Wang LN, McNicol ED. Pharmacological treatment for pain in Guillain-Barre syndrome. Cochrane Database Syst Rev 2015; CD009950
    PubMedGoogle Scholar
  • 47 Pandey CK, Raza M, Tripathi M, Navkar DV, Kumar A, Singh UK. The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit. Anesth Analg 2005; 101 (01) 220-225 table of contents
    CrossrefPubMedGoogle Scholar
  • 48 Peña L, Moreno CB, Gutierrez-Alvarez AM. Pain management in Guillain-Barré syndrome: a systematic review. Neurologia 2015; 30 (07) 433-438
    CrossrefPubMedGoogle Scholar
  • 49 van der Meché FG, Schmitz PI. Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326 (17) 1123-1129
    CrossrefPubMedGoogle Scholar
  • 50 Plasmapheresis and acute Guillain-Barré syndrome. The Guillain-Barré syndrome Study Group. Neurology 1985; 35 (08) 1096-1104
    CrossrefPubMedGoogle Scholar
  • 51 Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2014; (09) CD002063
    PubMedGoogle Scholar
  • 52 Hughes RA, Swan AV, Raphaël JC, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 2007; 130 (Pt 9) 2245-2257
    CrossrefPubMedGoogle Scholar
  • 53 Hughes RA. Plasma exchange versus intravenous immunoglobulin for Guillain-Barré syndrome. Ther Apher 1997; 1 (02) 129-130
    CrossrefPubMedGoogle Scholar
  • 54 Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997; 349 (9047) 225-230
    CrossrefPubMedGoogle Scholar
  • 55 Raphaël JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2012; (07) CD001798
    PubMedGoogle Scholar
  • 56 Mitchell CW, Bertorini TE. Principles and Guidelines of Immunotherapy in Neuromuscular Disorders. In: Bertorini TE. ed. Neuromuscular Disorders: Treatment and Management. Philadelphia, PA: Saunders Elsevier; 2011: 101-113
    Google Scholar
  • 57 Marn Pernat A, Buturović-Ponikvar J, Svigelj V, Ponikvar R. Guillain-Barré syndrome treated by membrane plasma exchange and/or immunoadsorption. Ther Apher Dial 2009; 13 (04) 310-313
    CrossrefPubMedGoogle Scholar
  • 58 Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2017; 2: CD001798
    PubMedGoogle Scholar
  • 59 The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 1997; 41 (03) 298-306
    CrossrefPubMedGoogle Scholar
  • 60 Lehmann HC, Hartung HP, Hetzel GR, Stüve O, Kieseier BC. Plasma exchange in neuroimmunological disorders: Part 1: rationale and treatment of inflammatory central nervous system disorders. Arch Neurol 2006; 63 (07) 930-935
    CrossrefPubMedGoogle Scholar
  • 61 Espérou H, Jars-Guincestre MC, Bolgert F, Raphaël JC, Durand-Zaleski I. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Cost analysis of plasma-exchange therapy for the treatment of Guillain-Barré syndrome. Intensive Care Med 2000; 26 (08) 1094-1100
    CrossrefPubMedGoogle Scholar
  • 62 Osterman PO, Fagius J, Lundemo G. et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984; 2 (8415) 1296-1299
    PubMedGoogle Scholar
  • 63 Tharakan J, Jayaprakash PA, Iyer VP. Small volume plasma exchange in Guillain-Barre syndrome: experience in 25 patients. J Assoc Physicians India 1990; 38 (08) 550-553
    PubMedGoogle Scholar
  • 64 Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 2004; 102 (03) 177-193
    CrossrefPubMedGoogle Scholar
  • 65 Brannagan III TH. Intravenous gamma globulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies. Neurology 2002; 59 (12) (Suppl. 06) S33-S40
    CrossrefPubMedGoogle Scholar
  • 66 Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993; 341 (8845) 586-590
    PubMedGoogle Scholar
  • 67 Hughes RA, Swan AV, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev 2010; (02) CD001446
    PubMedGoogle Scholar
  • 68 Hughes RA, Brassington R, Gunn A, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev 2016; 10: CD001446
    Google Scholar
  • 69 Susuki K, Yuki N. Effect of methylprednisolone in patients with Guillain-Barré syndrome. Lancet 2004; 363 (9416) 1236-1237 author reply 1237–1238
    PubMedGoogle Scholar
  • 70 van Koningsveld R, Schmitz PI, Meché FG, Visser LH, Meulstee J, van Doorn PA. Dutch GBS study group. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 2004; 363 (9404) 192-196
    CrossrefPubMedGoogle Scholar
  • 71 Ruts L, Drenthen J, Jacobs BC, van Doorn PA. Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology 2010; 74 (21) 1680-1686
    CrossrefPubMedGoogle Scholar
  • 72 Kuitwaard K, Bos-Eyssen ME, Blomkwist-Markens PH, van Doorn PA. Recurrences, vaccinations and long-term symptoms in GBS and CIDP. J Peripher Nerv Syst 2009; 14 (04) 310-315
    CrossrefPubMedGoogle Scholar
  • 73 Ishii J, Yuki N, Kawamoto M, Yoshimura H, Kusunoki S, Kohara N. Recurrent Guillain-Barré syndrome, Miller Fisher syndrome and Bickerstaff brainstem encephalitis. J Neurol Sci 2016; 364: 59-64
    CrossrefPubMedGoogle Scholar
  • 74 Notturno F, Kokubun N, Sekiguki Y. et al. Demyelinating Guillain-Barré syndrome recurs more frequently than axonal subtypes. J Neurol Sci 2016; 365: 132-136
    CrossrefPubMedGoogle Scholar